Health
Vaccine injury victims battle insurance companies over treatment coverage
Four people who say they suffered serious health complications following COVID-19 vaccination have accused health insurance companies of denying or restricting access to essential treatments, leaving them with worsening conditions and mounting medical expenses.
The patients, who spoke to The Defender, described prolonged battles with insurers over coverage for specialised medical procedures, diagnostic tests, prescriptions and treatments they said were necessary to manage their conditions.
According to their accounts, insurance companies frequently classified requested treatments as experimental or medically unnecessary, rejected referrals to specialists or discontinued therapies that had helped stabilise their health.
The affected individuals said the challenges cut across employer-sponsored health plans, private insurance and Medicare-related coverage, with some spending thousands of dollars out of pocket while struggling to obtain appropriate medical care.
Their accounts also raise questions about access to treatment for people reporting adverse reactions following COVID-19 vaccination.
The development comes after the Centers for Medicare & Medicaid Services introduced a new medical code to help physicians diagnose and treat vaccine injuries. The policy is scheduled to take effect on January 1, 2027, and will also be available to Medicaid providers and private insurers.
However, it remains unclear how widely private insurance companies will adopt the new code.
One of those affected is Danielle Baker, an Ohio-based registered nurse who said she developed severe neurological complications after receiving two doses of the Pfizer-BioNTech COVID-19 vaccine in June 2021.
Baker said she received the vaccines under pressure from her then-employer and was subsequently diagnosed with transverse myelitis, an inflammatory condition affecting the spinal cord.
READ ALSO; Israel, Pfizer face fresh scrutiny over early COVID vaccine heart safety reports
She said her health deteriorated so severely that she was declared totally disabled and awarded Social Security Disability Insurance benefits.
However, losing her employment also meant losing her previous health insurance coverage, forcing her to enrol in a high-deductible plan requiring $15,000 in out-of-pocket spending before coverage commenced.
Baker said the plan excluded several specialists, diagnostic tests and medications she needed, leaving her with substantial medical expenses.
Her situation did not improve significantly when she enrolled in Medicare in 2024 alongside supplemental coverage from Anthem Blue Cross Blue Shield.
According to her, insurance restrictions continued to prevent access to specialised care, particularly because she lacked the diagnostic coding required to justify certain treatments.
Baker identified intravenous immunoglobulin (IVIG), a therapy used in treating certain immune-related conditions, as the most beneficial treatment for her condition.
After several unsuccessful attempts to secure approval, she said a physician eventually diagnosed her with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder.
The diagnosis helped her obtain IVIG treatment in 2025, which she said stabilised her declining health and restored some quality of life.
However, the situation deteriorated again after Anthem discontinued her supplemental plan at the end of 2025.
Baker subsequently switched to UnitedHealthcare for supplemental Medicare coverage in 2026 but said the company rejected her renewed request for IVIG treatment.
She went without the therapy for six weeks, during which her condition rapidly worsened and required hospitalisation.
Although hospital staff eventually helped resolve what was described as a coding error, allowing her treatment to resume temporarily, subsequent requests were again rejected.
Baker said the insurer offered different reasons for denying coverage, including insufficient evidence of improvement and, paradoxically, concerns about the extent of her recovery.
She claimed the repeated interruptions forced her to seek emergency treatment approximately every six weeks to obtain limited supplies of IVIG.
According to Baker, the treatment costs approximately $12,000 every three weeks, an expense she said she cannot sustain without insurance support.
Another patient, Connecticut resident Kendall Smith, said she developed serious neurological symptoms after receiving her second dose of Moderna’s COVID-19 vaccine in October 2021.
Smith, who described herself as previously healthy, said she later experienced noticeable discoloration in her hands and was eventually diagnosed with non-length-dependent immune-mediated small fibre neuropathy and dysautonomia.
She said obtaining the diagnoses involved years of unsuccessful medical consultations and experiences in which doctors dismissed her symptoms.
Although she remains employed and has workplace health insurance, Smith said her insurer has resisted covering specialised diagnostic tests and treatments.
She cited a dysautonomia panel that cost her more than $1,000 out of pocket, alongside higher specialist co-payments and restrictions on certain prescriptions and therapies.
Smith also said her neurologist warned her to expect an initial rejection of IVIG treatment, noting that a large proportion of referrals submitted to insurance companies were reportedly denied.
She said her insurer, through a provider linked to RxBenefits, rejected her IVIG request on grounds that the treatment was not medically necessary and lacked sufficient supporting studies.
Several appeals, including a third-party review by the Medical Review Institute of America, were unsuccessful.
Smith said her symptoms have continued to worsen and that her neurologist believes earlier access to IVIG might have improved her condition.
She is now facing the possibility of long-term medication and IVIG treatment every three weeks for at least a year.
Meanwhile, California resident Erik Klint said his life changed dramatically after receiving a Johnson & Johnson COVID-19 booster in 2021.
Klint, a former video engineer who toured with rock bands, said he developed tremors and balance problems shortly after vaccination.
He claimed his mobility progressively declined, forcing him to move from using a cane to a walker before eventually becoming wheelchair-dependent.
“At 50, I walked my kids to school. By 52, I couldn’t walk to the bathroom,” he said.
Despite consulting 27 doctors, Klint said he has struggled to obtain a definitive diagnosis or effective treatment.
He also reported spending $9,000 on laboratory investigations, $1,500 on individual MRI scans and an additional $3,000 on an ambulance bill that his insurance did not cover.
Following a serious fall in October 2025 that left him with a broken shoulder and facial injuries, Klint spent nearly a month in an inpatient rehabilitation facility.
However, he said his insurer, Kaiser, cut short his rehabilitation after determining that his shoulder was healing and further treatment focused increasingly on his mobility problems.
His subsequent home-based physical and occupational therapy lasted only two and a half weeks before being discontinued.
Klint said he has since received little medical follow-up, rarely leaves his home and depends on neighbours for assistance with everyday activities.
The experiences of the four patients highlight the financial and medical difficulties some individuals reporting COVID-19 vaccine injuries say they face when seeking long-term treatment.